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Abstract
A novel Vero cell-derived inactivated WN vaccine (WN-VAX) was prepared from virus strain NY99-35262. Two immunizations with WN-
VAX induced high levels of neutralizing antibody to WN virus. All immunized mice were protected against challenge with a lethal dose of WN
virus. No WN viremia was detected, and the level of WN virus-neutralizing antibody increased rapidly. WN-VAX was then examined for
immunogenicity in mice previously immunized with Japanese encephalitis vaccine (JE-VAX). Immunization with WN-VAX induced WN virus-
neutralizing antibody in all mice previously immunized with JE-VAX but in only half of the control mice at 10 weeks. These results indicate that
WN-VAX induced complete protective immunity against lethal WN infection and that the WN-VAX-induced antibody response is facilitated in
JE-VAX-immunized mice. This WN-VAX is thus a candidate WN vaccine for humans.
© 2007 Elsevier Inc. All rights reserved.Keywords: West Nile virus; West Nile vaccine; Japanese encephalitis virus; Japanese encephalitis vaccine; Antibody response; FlavivirusIntroduction
West Nile (WN) virus was first isolated in 1937 from a
woman with mild febrile illness in the West Nile district of
Uganda (Smithburn et al., 1940). Over the past decade, WN
virus has re-emerged as a serious pathogen for humans and
horses (Bunning et al., 2002; Campbell et al., 2002). In humans,
WN fever is an acute febrile illness accompanied by malaise,
anorexia, nausea, vomiting, eye pain, headache, myalgia, rash,
and lymphadenopathy. Advanced age is the most significant risk
factor for severe neurologic involvement after infection with
WN virus (Petersen and Marfin, 2002). Outbreaks of WN fever
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doi:10.1016/j.virol.2007.12.021rate have occurred in Algeria (1994), Romania (1996), Israel
(1998–2000), and Russia (1999–2003) (Giladi et al., 2001; Le
Guenno et al., 1996; Lvov et al., 2000; Murgue et al., 2001; Tsai
et al., 1998). After an initial outbreak in 1999, large outbreaks
of WN fever have occurred annually in the United States (Cen-
ter for Disease Control and Prevention, 2006b; Hayes et al.,
2005; Mackenzie et al., 2004; Nash et al., 2001), and the virus
has spread to neighboring countries and areas, including Ca-
nada, Mexico, the Caribbean islands, Colombia, and Argentina
(Elizondo-Quiroga et al., 2005; Morales et al., 2006; Pepperell
et al., 2003).
Four WN vaccines have been licensed for veterinary use in
the United States and include an inactivated vaccine with ad-
juvant (West Nile-Innovator®; Fort Dodge Animal Health, Fort
Dodge, IA, USA) (Ng et al., 2003; Tesh et al., 2002a), a DNA
vaccine that is not yet available (Fort Dodge Animal Health)
(Turell et al., 2003; Yang et al., 2001), a recombinant vaccine
with adjuvant that consists of a canarypox virus vector with
insertion of the membrane (prM) and envelope (E) genes of the
Fig. 1. Schedules for blood collection after immunization with WN-VAX or JE-VAX and challenge with WN virus. Two experiments were performed to examine
efficacies of WN-VAX and JE-VAX against lethal WN virus challenge (A) and to assess WN virus- or JE virus-neutralizing antibody (B). White arrowheads indicate
the day of vaccination, black arrowhead indicates the day of WN virus challenge, and gray arrowheads indicate dates of blood collection.
Fig. 2. Protective effects of WN-VAX and JE-VAX against lethal WN virus
challenge. Ten mice were immunized twice with 0.5 ml two-fold-diluted WN-
VAX (white circles) or JE-VAX (gray circles) at a 7-day interval. Control mice
were injected with phosphate-buffered saline (black circles). Mice were
challenged with 1 LD50 (A) or 100 LD50 (B) WN virus at 4 weeks after the
second immunization, and survival rate was examined. Statistical analyses were
performed by chi-square test among control mice, mice immunized with WN-
VAX, and mice immunized with JE-VAX. P values between WN-VAX and JE-
VAX, WN-VAX and PBS, and JE-VAX and PBS are indicated.
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mited, Athens, GA, USA) (Minke et al., 2004), and a yellow
fever–WN chimera vaccine that contains the prM and E genes of
the WN virus (PreveNile™; Intervet, DeSoto, KS, USA) (Seino
et al., 2007). The chimera vaccine has been used successfully in
horses and exotic birds (Chang et al., 2007; Davidson et al.,
2005). However, a vaccine for human use is not yet available. A
new experimental inactivated WN vaccine (WN-VAX) without
adjuvant for use in humans has been prepared from Vero cell-
propagated WN virus by the Research Foundation for Microbial
Diseases of Osaka University (BIKEN) (Suita, Osaka, Japan).
WN and Japanese encephalitis (JE) viruses belong to the JE
antigenic complex of the genus Flavivirus in the family Flavi-
viridae (Chambers et al., 1990; Kuno et al., 1998; Mackenzie
et al., 2004; Mukhopadhyay et al., 2005). WN and JE viruses
are maintained in a natural cycle between mosquitoes and ver-
tebrate hosts (Chambers et al., 1990; Hamano et al., 2007;
Hayes et al., 2005). These two viruses are related serologically;
infection or vaccination with one virus induces partial pro-
tective immunity against the other in laboratory animals (Ham-
mon and Sather, 1956; Takasaki et al., 2003; Tesh et al., 2002b).
Consequently, there is considerable concern and scientific
interest regarding the invasion of WN virus into JE virus-
endemic regions (Hamano et al., 2007; Solomon et al., 2003;
Tiroumourougane et al., 2002). In Asia, licensed mouse brain-
derived inactivated JE vaccine (JE-VAX) has been used for
more than 40 years, and the effect of JE-VAX immunization on
the immune response to WN-VAX is the subject of intensive
research (Hoke et al., 1988; Kurane and Takasaki, 2000; Oya,
1988; Sohn, 2000; Tsai, 2000).
In the present study, protective immunity of WN-VAX or JE-
VAX against lethal WN virus infection was analyzed in mice.
Protective mechanisms, with a focus on viremia and neutraliz-
ing antibody were also analyzed. In addition, the effect of JE-
VAX immunity on the antibody response to WN-VAX was
assessed.
Results
Induction of complete and partial protective immunity against
lethal WN virus infection by inactivated WN-VAX and JE-VAX,
respectively
Protection assays were conducted in mice to determine the
efficacy ofWN-VAX and JE-VAX in the prevention of lethalWN
virus infection. Groups of 10 C3H/HeN mice were immunized
with 0.5 ml two-fold-dilutedWN-VAX or JE-VAX. Control micewere injected with phosphate-buffered saline (PBS). A second
immunization was given 7 days later. Four weeks after the second
immunization,micewere challenged intraperitoneallywith a 50%
lethal dose (1 LD50) or a 100-fold higher concentration (100
LD50) of WN virus (Fig. 1A). Mice were observed for symptoms
and survival for 8 weeks. Survival curves are shown in Fig. 2.
Nine of 10 control mice died after challenge with 1 LD50 WN
virus and all control mice died after challenge with 100 LD50WN
virus. All mice immunized with WN-VAX survived challenge
with 1 LD50 or 100 LD50WN virus. Four of 10 (PN0.05 vs. PBS)
and three of 10 (Pb0.05 vs. PBS) mice immunized with JE-VAX
survived challenge with 1 LD50 and 100 LD50 WNV. These
results indicated that WN-VAX induced complete protective
immunity against lethalWNvirus infection, and JE-VAX induced
partial protection.
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Viremia was determined according to WN virus RNA copy
number on days 3, 6, and 13 after challenge with 1 LD50
(Fig. 3A–C) or 100 LD50 (Fig. 3D–F) WN virus. High levels of
viremia were detected on days 3 and 6 after challenge in
unimmunized mice, except for mice that survived. In contrast,
viremia was not detected at any time point in mice immunized
with WN-VAX.
Viremia was detected in six of 10 and 9 of 10 mice im-
munized with JE-VAX on day 3 after challenge with 1 LD50 and
100 LD50 WN virus, respectively. Viremia was not detected in
mice that survived. In seven of 10 mice immunized with JE-
VAX and challenged with 100 LD50 WN virus, viremia was
eliminated on day 6 or 13. Two of the 5 mice still alive on day
13 died during the 8-week observation period. These results
were consistent with those in Fig. 2 and suggested that WN-
VAX induced protective immunity against WN virus, whereas
JE-VAX induced partial protective immunity.
Serum neutralizing antibody responses to WN and JE viruses
after WN virus challenge in mice immunized with WN-VAX or
JE-VAX
Titers of neutralizing antibodies to WN and JE viruses were
assessed by 50% focus reduction neutralization test (FRNT50)Fig. 3. Time course ofWN viremia after challenge withWN virus. Ten mice were imm
interval. Control mice were injected with phosphate-buffered saline (C, F). Mice were
second immunization. Individual blood samples were collected at 3, 6, and 13 days afte
transcription-polymerase chain reaction. Black squares and white triangles indicate
indicates the mean number of viral RNA copies. The detection limit of RNA copiesafter two immunizations with WN-VAX or JE-VAX and
challenge with WN virus. Sera were collected on days 0, 21,
35, 38, 41, 48, 56, 63, 77, and 91. Day 0 was defined as the day
of first immunization, and the mice were challenged with WN
virus on day 35. Two immunizations with WN-VAX induced
neutralizing antibody to WN virus, and the antibody was cross-
reactive with JE virus (Fig. 4B–C and L–M). Two immuniza-
tions with JE-VAX induced neutralizing antibody to JE vi-
rus, but the antibody was not cross-reactive with WN virus
(Fig. 4B–C and L–M).
In WN-VAX-immunized mice challenged with 1 LD50 WN
virus, the level of neutralizing antibody toWN virus increased as
early as 3 days after challenge, decreased slightly over the next
10 days, and remained at this level until day 91 (Fig. 4D–J).
After challenge with 100 LD50 WN virus, the level of neu-
tralizing antibody to WN virus increased as early as 3 days after
challenge and remained at this level until day 91 (Fig. 4N–T).
The ratio of JE virus-neutralizing antibody titer to WN virus-
neutralizing antibody titer was less than 1 in 90% of mice at
3 days after challenge with WN virus, suggesting that the
neutralizing antibody titer was higher against WN virus than
against JE virus after WN virus challenge (Fig. 4D, N, Tables 1
and 2).
In JE-VAX-immunized mice challenged with WN virus, WN
virus-neutralizing antibody was first detected in a small per-
centage of mice 3 days after challenge and in most mice 6 daysunized twice with two-fold-dilutedWN-VAX (A, D) or JE-VAX (B, E) at a 7-day
challenged with 1 LD50 (A–C) or 100 LD50 (D–F) WN virus at 4 weeks after the
r challenge, and the viral RNA copy number was determined by real-time reverse
dead and surviving mice at 3 weeks post-challenge, respectively. Asterisks (⁎)
was 100 copies per ml.
Fig. 4. Levels of JE virus- and WN virus-neutralizing activity after WN virus challenge in mice immunized with WN-VAX or JE-VAX. Ten mice were immunized
twice with 0.5 ml two-fold-diluted WN-VAX (black diamonds) or JE-VAX (white circles) at a 7-day interval. Control mice were injected with phosphate-buffered
saline (white triangles). Mice were challenged with 1 LD50 (A–J) or 100 LD50 (K–T) WN virus on day 35 (4 weeks after the second immunization). Sera were
collected on days 0 (A, K), 21 (B, L), 35 (C, M), 38 (D, N), 41 (E, O), 49 (F, P), 56 (G, Q), 63 (H, R), 77 (I, S), and 91 (J, T). Day 0 was the day of first immunization.
Neutralizing antibody titers to WN and JE viruses were determined by 50% focus reduction neutralization test (FRNT50).
63C.-K. Lim et al. / Virology 374 (2008) 60–70after challenge (Fig. 4D–E and N–O). Interestingly, the level of
JE virus-neutralizing antibody also increased after WN virus
challenge. The ratio of JE virus-neutralizing titer to WN virus-
neutralizing titer was greater than 1 on day 41, suggesting that
the neutralizing antibody titer was higher against JE virus than
against WN virus (Tables 1 and 2). In 10 unimmunized mice
challenged with WN virus, WN virus-neutralizing antibody was
detected in one mouse 3 days after challenge and in most of the
other mice 6 days after challenge; these mice eventually died.
There was no apparent difference in WN virus-neutralizing
antibody titer between JE-VAX-immunized and unimmunized
mice on day 41.
Enhancing effect of cross-reactive immunologic memory
induced by JE-VAX on the WN-VAX-induced antibody response
It is possible that some individuals will be vaccinated
successively with JE-VAX and WN-VAX. Therefore, antibody
responses to successive immunization with JE-VAX and WN-VAX were analyzed. Ten mice were immunized with two-fold-
diluted JE-VAX and then with two-fold-diluted WN-VAX
8 weeks apart (JE-VAX/WN-VAX). Other groups were
immunized with JE-VAX alone on day 0 (JE-VAX/PBS) or
with WN-VAX alone at 8 weeks (PBS/WN-VAX). Sera were
collected on day 0 and at weeks 2, 4, 8, 9, 10, 11, 12, 14, and 16
(Fig. 1B). Day 0 was defined as the day of first immunization
with JE-VAX.
Before immunization with WN-VAX at 8 weeks, only two of
the 10 mice in the JE-VAX/WN-VAX group showed a de-
tectable level of WN virus-neutralizing antibody. After im-
munization, WN virus-neutralizing antibody was detected in
eight of 10 mice at week 9 (7 days after second immunization)
and in all mice at week 10. The titer increased rapidly until week
11. WN virus-neutralizing antibody was detected in only two of
10 mice in the PBS/WN-VAX group at week 9, in five mice at
week 10, and in seven mice at week 11. The titer was not as high
as that in the JE-VAX/WN-VAX group. At week 12 and
thereafter, WN virus-neutralizing antibody was detected in all
Table 1
Ratios of JE/WN neutralization titers in mouse serum challenged with 1 LD50 WN virus NY99
VAX ID# Ratios of JE/WN neutralization titers (WN neutralization titer) a
0 c 21 35 d 38 41 48 56 63 77 91 (day b)
WN 1–1 – b1/8 (160) b1/2 (40) 1/64 (2560) 1/16 (640) 1 (160) 1/4 (640) 1 (160) 1/4 (160) 1/8 (160)
1–2 – 1/8 (160) 1 (40) 1/16 (640) 1/16 (640) 1 (160) 1 (160) 1/4 (160) 1/8 (160) b1/8 (160)
1–3 – 1/4 (160) 1/2 (40) b1/128 (2560) 1/16 (2560) 1 (160) 1 (160) 1 (160) 1/4 (160) 1/4 (640)
1–4 – 4 (40) 1 (40) 1/16 (2560) 1 (160) 1/4 (640) 1/4 (640) 1/4 (640) 1/4 (640) 1 (160)
1–5 – 1/4 (640) 1 (40) 1/16 (640) 1 (160) 1 (160) 1 (160) 1 (160) 1/4 (160) 1/4 (160)
1–6 – 8 (20) 1 (40) 1/32 (640) 1/4 (160) 1 (160) 1/4 (640) 1 (160) 1/4 (160) 1/32 (640)
1–7 – 1 (160) 1/4 (160) 1/64 (2560) 1 (160) 1 (160) 1/4 (640) 1/4 (640) 1/4 (160) 1/16 (640)
1–8 – 2 (20) 4 (40) 1/4 (640) 1/4 (160) 1 (160) 4 (160) 1 (160) 1 (160) 1/4 (160)
1–9 – 8 (20) 1/2 (40) 1/4 (160) 1 (160) 1/8 (160) 1/4 (160) 1/4 (160) 1 (40) 1/4 (160)
1–10 – 1/2 (40) 1 (40) 1/4 (640) 1/16 (640) 1/4 (160) 1 (160) 1/4 (160) 1/16 (640) 1/4 (160)
JE 2–1 – N32 (b20) N8 (b20) N128 (b20) 128 (20) 128 (20) 64 (40) 64 (40) 128 (20) N32 (b20)
2–2 – N2 (b20) N8 (b20) N32 (b20) N32 (b20) † † † † †
2–3 – N1 (b20) N1 (b20) N8 (b20) N2 (b20) † † † † †
2–4 – N2 (b20) N8 (b20) N8 (b20) 4 (40) 64 (40) 4 (40) 1 (160) 16 (40) 4 (40)
2–5 – N32 (b20) N8 (b20) N128 (b20) 32 (20) 64 (40) 4 (40) 1 (160) 4 (40) 4 (40)
2–6 – N32 (b20) N8 (b20) 16 (40) 16 (40) † † † † †
2–7 – N32 (b20) N2 (b20) 32 (20) 16 (40) † † † † †
2–8 – N8 (b20) N2 (b20) N32 (b20) 8 (20) † † † † †
2–9 – N128 (b20) N32 (b20) N128 (b20) 16 (40) 16 (160) 16 (160) 64 (40) 16 (40) 4 (160)
2–10 – N8 (b20) N8 (b20) N128 (b20) N8 (b20) † † † † †
PBS 3–1 – – – – 8 (20) † † † † †
3–2 – – – – 1 (40) † † † † †
3–3 – – – – 1 (160) † † † † †
3–4 – – – – N8 (b20) † † † † †
3–5 – – – – 1 (40) † † † † †
3–6 – – – – 4 (40) 1/32 (640) b1/2 (40) b1 (20) b1 (20) –
3–7 – – – – 2 (20) † † † † †
3–8 – – – – N8 (b20) b1/128 (2560) † † † †
3–9 – – – – N8 (b20) † † † † †
3–10 – – – b1 (20) 4 (40) b1/32 (640) † † † †
†: Death from WN virus infection.
–: Both JE and WN neutralization titers are less than 20.
a WN neutralization titers are shown in parentheses.
b Day post first immunization.
c Day of first immunization with WN-VAX, JE-VAX, or phosphate-buffered saline (PBS).
d Day of challenge with WN virus NY99.
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similar to that in the JE-VAX/WN-VAX group. The JE virus-
neutralizing antibody titer was also increased in eight of the 10
mice in the JE-VAX/WN-VAX group during the 3-week period
after immunization with WN-VAX (Figs. 5 and 6E–J, Table 3).
These results indicated that immunologic memory induced by
JE-VAX facilitated the WN virus-neutralizing antibody
response after WN-VAX immunization and that immunization
with WN-VAX enhanced the level of JE virus-neutralizing
antibody in mice previously immunized with JE-VAX.
Discussion
In the United States alone, the reported number of humanWN
virus cases has exceeded 23,000 since it was first reported in
New York City in 1999 (Centers for Disease Control and
Prevention, 2006a,b). A vaccine against WN virus has become
highly desirable. Several WN vaccines have been licensed for
veterinary use. However, multiple scientific issues have to be
addressed before aWN vaccine will be approved for human use.
The experimental WN-VAX was developed according to theproduction protocol for an inactivated Vero cell-derived JE
vaccine (v-JE-VAX), which is highly purified, adjuvant free, and
shows similar levels of immunogenicity to the currently used
mouse brain-derived, inactivated JE-VAX (Ishikawa, 2007;
Ishikawa, 2005; Srivastava et al., 2001; Tsai, 2000).
In the present study, we analyzed the protective efficacy of
WN-VAX against the WN virus in a mouse model that is used
widely for histopathologic, pathogenic, and immunologic
analyses of experimental WN virus infection (Brinton et al.,
1982; Garcia-Tapia et al., 2007). Inbred mouse strains show
significant differences in susceptibility to flaviviruses, including
WN and JE viruses, due to a single gene, Flv, which has been
mapped to mouse chromosome 5 (Miura et al., 1988; Perelygin
et al., 2002). We used C3H/HeN mice, which are susceptible to
flaviviruses (Brinton et al., 1982). The LD50 of the WN virus
was determined after intraperitoneal administration by the me-
thod of Reed and Muench (1938) and was identified at 1.3×101
plaque-forming units (PFU) containing 8.0×101 copies of WN
virus RNA. One (10%) of 10 control mice pre-injected with
PBS survived challenge with 1 LD50WN virus without showing
detectable viremia (Figs. 2A and 3C). However, this mouse
Table 2
Ratios of JE/WN neutralization titers in mouse serum challenged with 100 LD50 WN virus NY99
VAX ID# Ratios of JE/WN neutralization titers (WN neutralization titer) a
0 c 21 35 d 38 41 48 56 63 77 91 (day b)
WN 4–1 – 1/16 (640) 1/4 (640) 1/4 (640) 1/16 (640) 1/4 (640) 1/16 (2560) 1/4 (640) 1/4 (640) 1/16 (640)
4–2 – 1 (40) 4 (40) 1/4 (160) 4 (40) 1/4 (640) 1/64 (2560) 1/4 (160) 1/4 (160) b1/32 (640)
4–3 – 1 (40) 1 (40) 1/4 (160) 1 (40) 1/32 (640) 1/32 (640) 1/16 (640) 1/32 (640) b1/32 (640)
4–4 – 1/4 (160) 4 (40) 1/4 (160) 1 (160) 1/32 (640) 1/4 (640) 1/4 (640) 4 (160) 1/4 (640)
4–5 – – 1/2 (40) 1 (40) 1 (160) 1/4 (640) 1/32 (640) 1/8 (160) 1/8 (160) 1 (40)
4–6 – 1 (40) 1 (40) b1/32 (640) 1 (160) 1/4 (640) 1/16 (640) 1/16 (640) 1/4 (160) 1/16 (640)
4–7 – 2 (20) 1 (40) 1 (40) 1 (160) 1/32 (640) 1/16 (640) 1/4 (160) 1/4 (160) 1 (160)
4–8 – 1/2 (40) 1/4 (160) 1/16 (640) 1 (160) 1/4 (640) 1/16 (2560) 1/16 (2560) 1/4 (640) 1 (640)
4–9 – 4 (40) 1 (160) 1/4 (640) 1 (160) 1/16 (640) 1/16 (2560) 1/4 (640) 4 (640) 1 (640)
4–10 – b1/2 (40) 1/2 (40) 1/16 (640) 1/4 (640) 1/16 (2560) 1/64 (2560) 1/16 (640) 1/16 (640) b1/32 (640)
JE 5–1 – 128 (20) N32 (b20) N128 (b20) 16 (160) 16 (160) 4 (640) 4 (640) 16 (160) 1 (160)
5–2 – N2 (b20) N1 (b20) 8 (20) 1 (160) 4 (40) † † † †
5–3 – N32 (b20) N32 (b20) N128 (b20) 16 (160) 16 (160) 1 (2560) 4 (640) 16 (160) 1 (160)
5–4 – N8 (b20) N2 (b20) N8 (b20) 1 (160) † † † † †
5–5 – N32 (b20) N8 (b20) N32 (b20) 4 (160) † † † † †
5–6 – N32 (b20) N32 (b20) N128 (b20) 16 (40) 4 (160) 1 (640) 4 (640) 4 (640) 1/4 (640)
5–7 – N32 (b20) N128 (b20) N128 (b20) 16 (160) 4 (40) † † † †
5–8 – N2 (b20) N8 (b20) N32 (b20) 4 (40) † † † † †
5–9 – N32 (b20) N128 (b20) N128 (b20) 16 (40) † † † † †
5–10 – N2 (b20) N8 (b20) N128 (b20) 4 (160) † † † † †
PBS 6–1 – – – – 1/4 (160) † † † † †
6–2 – – – – 1 (40) † † † † †
6–3 – – – – 1 (40) † † † † †
6–4 – – – – 1 (160) † † † † †
6–5 – – – – 1 (160) † † † † †
6–6 – – – – 1 (160) † † † † †
6–7 – – – – 1/2 (40) † † † † †
6–8 – – – – 1/4 (160) † † † † †
6–9 – – – – 1/4 (160) † † † † †
6–10 – – – b1 (20) 1 (160) † † † † †
†: Death from WN virus infection.
–: Both JE and WN neutralization titers are less than 20.
a WN neutralization titers are shown in parentheses.
b Day post first immunization.
c Day of first immunization with WN-VAX, JE-VAX, or phosphate-buffered saline (PBS).
d Day of challenge with WN virus NY99.
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(Table 1). All control mice challenged with 100 LD50 WN virus
showed high levels of viremia and died (Figs. 2B and 3F).
Therefore, intraperitoneal challenge resulted in accurate assess-
ment of vaccine efficacy.
It is generally agreed that neutralizing antibody is the major
mediator of protective immunity against flaviviruses and acts by
blocking viremia and subsequent infection of the brain. The
primary target of virus-neutralizing antibody is the E protein,
which is the major determinant of virus tropism (Beasley and
Barrett, 2002). Thus, the ability to induce high levels of neu-
tralizing antibody is essential for protective efficacy of any
flavivirus vaccine (Aberle et al., 2005; Konishi et al., 2003;
Pugachev et al., 2003). It is possible that cellular immunity also
play a role in recovery from WN virus infection. Cellular
immune responses were not analyzed in the present study, but
need to be addressed in the future study.
The obtained sample volume was limited, therefore, to deter-
mine induced neutralizing antibody titers in serially collected
samples of mouse serum, we developed a FRNT50 assay (Okuno
et al., 1978). FRNT50 assays require small amounts of samplesera, indicator cells, medium, and incubator space; 96-well
plates are used for cell cultivation and serum dilution. The entire
assay requires as few as 3 days. Neutralizing antibody titers
obtained with FRNT50 assays show good agreement with those
obtained by 50% plaque reduction neutralization test (PRNT50)
(Okuno et al., 1985).
We found that a single WN-VAX immunization was not
sufficient to induce WN virus-neutralizing antibody in all mice
(Fig. 5A). However, all mice immunized twice developed
neutralizing antibody (Fig. 4C, M). Neutralizing antibody ti-
ters was increased by 3 days after WN virus challenge (Fig. 4D,
N). WN virus challenge was well tolerated (Fig. 2), and WN
viral RNAwas not detected in blood samples collected at 3, 6,
and 13 days after challenge (Fig. 3A, D). These results
indicated that neutralizing antibody induced by WN-VAX
efficiently protected mice from lethal WN virus infection.
Although we showed protection only against WN virus, WN-
VAX may be protective against JE virus to the same degree
because a cross-neutralizing titer was induced by two WN
immunizations (Fig. 4B, L). Challenge experiments will be
necessary to confirm this.
Fig. 5. Percentages of mice with neutralizing antibody to WN and JE virus at
titers of 1:20 or greater after immunization with JE-VAX and/or WN-VAX. Ten
mice were immunized twice at an 8-week-interval, with 0.5 ml two-fold-diluted
JE and WN vaccine (JE-VAX/WN-VAX) (black diamonds), 10 mice were
immunized with JE vaccine and phosphate-buffered saline (JE-VAX/PBS)
(white circles), and 10 mice were immunized with PBS and WN vaccine (PBS/
WN-VAX) (white triangles). Sera were collected on days 0, 2, 4, 8, 9, 10, 11, 12,
14, and 16. Day 0 was the day of first immunization. Neutralizing antibody titers
were determined by 50% focus reduction neutralization test (FRNT50) against
WN (A) and JE (B) viruses, and the percentages of mice with neutralizing
antibody at a titer of 1:20 or greater are shown.
Fig. 6. Neutralizing antibody titers to JE and WN viruses after immunization with W
diluted JE-VAX andWN-VAX (black diamonds), JE-VAX and phosphate-buffered sa
Serum samples were collected on day 0 (A) and weeks (wk) 2 (B), 4 (C), 8 (D), 9
immunization. Neutralizing antibody titers to JE and WN viruses were determined b
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of neutralizing antibody to JE virus, but cross-neutralizing
antibody to WN virus was not detected even after two im-
munizations. These results suggested that JE-VAX did not
induce high levels of neutralizing antibody cross-reactive to
WN virus (Fig. 4C, M). These observations are similar to those
of a previous report that protective neutralizing antibody titer
against WN virus was not detected in human volunteers, despite
successful immunization with JE-VAX (Kanesa-Thasan et al.,
2002). Interestingly, three of 10 JE-VAX-immunized mice
survived challenge with 100 LD50 WN virus by rapidly clearing
the virus from the blood, suggesting that partial protection
against WN virus is possible in the absence of detectable levels
of cross-neutralizing antibody to WN virus (Figs. 2 and 3E).
The WN and JE viruses show a high level of amino acid
homology but are antigenically distinct. Our present results are
in agreement with those of recent studies showing that JE
vaccine induces partial protection against WN virus challenge
in a murine model (Hammon and Sather, 1956; Takasaki et al.,
2003). This WN-VAX is an inactivated vaccine; therefore, it is
unlikely that this vaccine would have a detrimental effect in
other flavivirus antibody-positive vaccinees. However a pos-
sible detrimental effect of WN-VAX-induced cross-reactive
antibody on other flavivirus infection is an important scientific
issue that needs to be addressed in future study.
When introducingWN-VAX to JE virus-endemic areas, it will
be important to analyze immune responses in a population that has
immunity induced by natural infection or JE-VAX vaccination. It
has been reported that there are cross-reactive antibody responses
among flaviviruses which are concomitant with natural infectionN-VAX and/or JE-VAX. Ten mice were immunized twice with 0.5 ml two-fold-
line (white circles), or PBS andWN-VAX (white triangles) at a 2-month interval.
(E), 10 (F), 11 (G), 12 (H), 14 (I), and 16 (J). Day 0 was the day of the first
y 50% focus reduction neutralization test (FRNT50).
Table 3
Ratios of JE/WN neutralization titers in mouse serum immunized with JE- and/or WN-VAX
VAX ID# Ratios of JE/WN neutralization titers (WN neutralization titer) a
0 c 2 4 8 d 9 10 11 12 14 16 (week b)
JE-VAX/WN-VAX 7–1 – – – N2 (b20) 2 (20) 1/4 (160) 1/4 (160) 1/16 (640) 1/4 (160) 1/4 (160)
7–2 – N8 (b20) N8 (b20) N2 (b20) 8 (20) 1 (160) 1/4 (160) 1 (160) 1 (40) 1 (40)
7–3 – N8 (b20) N32 (b20) N8 (b20) N8 (b20) 1 (160) 1 (640) 16 (40) 4 (40) 16 (40)
7–4 – – b1 (20) N2 (b20) N2 (b20) 4 (40) 1/4 (160) 1 (160) 4 (40) 1 (40)
7–5 – N8 (b20) 8 (20) N8 (b20) 4 (40) 4 (40) 1 (160) 1 (160) 4 (40) 4 (40)
7–6 – – N1 (b20) – 16 (160) 4 (160) 1 (640) 4 (160) 4 (160) 16 (160)
7–7 – – – – 1 (20) 1/32 (640) 1/16 (640) 1/4 (160) 1 (40) 1/2 (40)
7–8 – – – – 1/2 (40) 1/16 (640) 1/16 (640) ‡ ‡ ‡
7–9 – N1 (b20) N1 (b20) 2 (20) 1/4 (640) 1/4 (160) 1/16 (640) ‡ ‡ ‡
7–10 – N2 (b20) N2 (b20) 4 (40) 1 (40) 4 (160) 4 (160) 1 (160) 4 (40) 4 (40)
JE-VAX/PBS 8–1 – – – N1 (b20) – – – – N1 (b20) –
8–2 – – – N1 (b20) – N1 (b20) N2 (b20) – – –
8–3 – – N8 (b20) N2 (b20) N2 (b20) N2 (b20) N1 (b20) N2 (b20) N2 (b20) N2 (b20)
8–4 – – – b1 (20) – N1 (b20) N1 (b20) N1 (b20) N1 (b20) N1 (b20)
8–5 – – N2 (b20) N2 (b20) N2 (b20) N1 (b20) N2 (b20) N2 (b20) N1 (b20) N2 (b20)
8–6 – N1 (b20) – – – – – N1 (b20) – –
8–7 – – N1 (b20) N2 (b20) N1 (b20) N2 (b20) N1 (b20) N2 (b20) – –
8–8 – N2 (b20) N8 (b20) N8 (b20) N8 (b20) N8 (b20) N8 (b20) N2 (b20) N1 (b20) N2 (b20)
8–9 – N8 (b20) N2 (b20) N2 (b20) N2 (b20) N1 (b20) N2 (b20) N2 (b20) N2 (b20) N2 (b20)
8–10 – N8 (b20) N8 (b20) N8 (b20) N8 (b20) ‡ ‡ ‡ ‡ ‡
PBS/WN-VAX 9–1 – – – – – b1 (20) b1 (20) b1/8 (160) b1/8 (160) b1/2 (40)
9–2 – – – – – N1 (b20) 1 (20) 1/2 (40) 1/8 (160) b1 (20)
9–3 – – – – – – – b1/2 (40) b1/8 (160) b1/8 (160)
9–4 – – – – – b1/2 (40) b1/2 (40) b1/8 (160) b1/8 (160) b1/8 (160)
9–5 – – – – b1 (20) b1/2 (40) b1/8 (160) b1/2 (40) b1/2 (40) b1/8 (160)
9–6 – – – – – – – b1/2 (40) – –
9–7 – – – – b1 (20) – b1 (20) – b1 (20) b1 (20)
9–8 – – – – – – – – b1 (20) –
9–9 – – – – – 1/8 (160) 1/2 (40) 1/16 (640) 1/4 (640) 1/4 (640)
9–10 – – – – – b1/8 (160) 1/8 (160) 1/8 (160) 1/8 (160) b1/8 (160)
‡: Death due to anesthesia.
–: Both JE and WN neutralization titers are less than 20.
a WN neutralization titers are shown in parentheses.
b Weeks post first immunization.
c Week of first immunization with JE-VAX or phosphate-buffered saline (PBS).
d Week of second immunization with WN-VAX or PBS.
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flaviviruses in vivo (Center for Disease Control and Prevention,
2006b; Kayser et al., 1985; Tesh et al., 2002b; Yamada et al.,
2003; Yamshchikov et al., 2005). After a single vaccination with
JE-VAX, only three (15%) of 20mice developed low titers ofWN
virus cross-neutralizing antibody by 8 weeks (Fig. 6D). Inter-
estingly, all mice that had been immunized once with JE-VAX
developed high levels of WN virus-neutralizing antibody by
2 weeks after immunization with WN-VAX. In addition, the
cross-neutralizing antibody response toWN-VAXwas rapid, with
80% of mice becoming seropositive by day 7. In mice not
immunized with JE-VAX, a single dose of WN-VAX-induced
neutralizing antibody in only half of mice by 2 weeks. These
results suggested that two immunizations with WN-VAX are
required to induce a high level of neutralizing antibody response
to WN virus in naïve populations, but that a single immunization
may be sufficient in JE pre-immune populations.
In summary, we found that all mice immunized with inac-
tivated WN-VAX were protected against challenge with lethal
doses of WN virus and showed no detectable viremia. In con-
trast, JE-VAX-vaccinated mice were partially protected againstWN virus. Mice pre-immunized with JE-VAX, which may be a
model for populations in JE virus-endemic areas, developed
sufficient levels of neutralizing antibody to WN virus after a
single WN vaccination. This Vero cell-derived, inactivated WN-
VAX is thus a candidate WN vaccine for humans.
Materials and methods
Mice
To avoid fighting among male mice, 21-day-old female
C3H/HeN mice were purchased from Charles River Labora-
tories Japan, (Yokohama, Kanagawa, Japan) and used at the age
of 4 weeks unless otherwise stated. Mice were maintained in
separate cages and kept in the vivarium until use; food and
water were available ad libitum.
Cell culture and viruses
Vero cells were obtained from the American Type Culture
Collection (Manassas, VAUSA) and grown in Eagle's minimum
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USA) containing 10% fetal bovine serum (FBS). Cells were
maintained in a humidified atmosphere at 37 ˚C in 5% CO2 and
were used for growing virus stocks and determining virus titra-
tions. West Nile virus strain NY99-6922 (GenBank accession
no. AB185915) was used. Virus suspensions were collected to
determine viral RNA copy number and viral titer. Viral titer was
measured in confluent Vero cell monolayers in 6-well plates by
plaque assay and was expressed as plaque-forming units (PFU)
per ml. In brief, plates were incubated at 37 ˚C for 60min in a 5%
CO2 incubator after inoculation with 100 μl virus. The plates
were tilted gently every 15 min. Two milliliters of 1% meth-
ylcellulose containing overlay medium was added to each well,
and the plates were incubated at 35 ˚C in a 5% CO2 incubator for
5 days. Cells were fixed with 10% formaldehyde (Wako Pure
Chemical Industries, Osaka, Japan) in PBS at room temperature
for 1 h. The methylcellulose was aspirated, wells were washed
three times and stained with methylene blue tetrahydrate
solution in distilled water, and the number of plaques in each
well was counted. The LD50 in mice was calculated by the
method of Reed and Muench (1938). WN virus (1.3×101
plaque-forming units) containing 8.0×101 copies virus RNA
was calculated as the LD50 by intraperitoneal inoculation.
Animal immunization and virus challenge
Mouse brain-derived formalin-inactivated JE vaccine (JE-
VAX) was purchased from BIKEN, Suita, Osaka, Japan. Vero
cell-derived formalin-inactivatedWN vaccine from strain NY99-
35262 (WN-VAX) was provided by Mr. Toyokazu Ishikawa,
BIKEN (Ishikawa, 2007). Both vaccines were diluted at 1:2 with
PBS and used for immunization. Four-week-old C3H/HeN mice
were intraperitoneally injected with 0.5 ml JE-VAX or WN-VAX
and immunized again 1 or 8 weeks after the initial immunization.
The animals were bled at 0, 14, 21, 28, 35, 38, 41, 48, 56, 63, 70,
77, 84, 91, 98, and 112 days after the first immunization, and
serum antibody levels were assessed. The day of the first
immunization was defined as day 0. All serum specimens were
inactivated at 56 ˚C for 30 min before assay and diluted with
EMEM containing 10% heat-inactivated FBS.
Some mice were immunized twice, 7 days apart, challenged
intraperitoneally with 1 LD50 or 100 LD50 WN virus NY99-
6922 5 weeks after the first immunization, and the viral RNA
copy number and serum antibody levels were assessed.
Antibody titration
Antibodies to WN virus were measured by FRNT50 (Okuno
et al., 1985). The virus stock was diluted to 4×103 focus-
forming units per ml and used as the challenge virus. Mouse sera
were first diluted 1:20 and then two-fold from 1:40 to 1:10,240
in EMEM containing 10% FBS. Equal volumes of diluted serum
and virus were mixed and incubated at 37 ˚C for 90min. Twenty-
five microliters of virus–serum mixture was inoculated onto
confluent Vero cell monolayers in 96-well plates. Plates were
incubated at 37 ˚C for 60 min in a 5% CO2 incubator to allow for
virus adsorption and were tilted gently every 15 min. One-hundred microliters EMEM with 10% FBS was added to each
well, and the plates were incubated at 37 ˚C in a 5% CO2
incubator for 2 days. Cells were washed three times with PBS
and fixed in 95% ethanol at room temperature. Focus staining
was performed by successive treatments of cells with rabbit anti-
JE or anti-WN serum (1:1000), raised by immunization with JE-
VAX or WN-VAX, goat anti-rabbit IgG serum (1:500) (Dako,
Glostrup, Denmark), and peroxidase–rabbit anti-peroxidase
complex (1:1000) (Dako). Each treatment was performed for
30 min and followed by a wash in PBS. In the final peroxidase–
anti-peroxidase step, the peroxidase reaction was developed for
approximately 10 min in the presence of 0.01% H2O2 and
0.3 mg/ml 3-3'-diaminobenzidine tetrahydrochloride (Sigma-
aldrich) in PBS. Cultures were rinsed with tap water and air
dried, and the number of foci in each well was counted (Okuno
et al., 1985).
Determination of viral RNA levels in WN viral particles
WN virus RNA was extracted from mouse blood with a
Magtration System 12GC (Precision System Science, Matusudo,
Chiba, Japan). A TaqMan Ez RT-PCR kit (Applied Biosystems,
Foster, CA, USA) was used to determine RNA copy numbers in
the samples. Forward and reverse primers (5'-tcagcgatctctccac-
caaag-3' and 5'-gggtcagcacgtttgtcattg-3') were used to amplify a
69-bp segment of the viral RNA with dual fluorophore-labeled
probe [5'-(6-carboxy-fluorescein)-tgcccgaccatgggagaagctc-(6-
carboxy-tetramethyl-rhodamine)-3']. Amplified products were
monitored with a PRISM 7000 Sequence Detection System
(Applied Biosystems), and the copy number in each sample was
determined on the basis of a standard curve createdwith a standard
density of in vitro-synthesized WN virus RNA, provided by Dr.
Soichi Nukuzuma, Kobe Institute of Health, Kobe, Hyogo, Japan.
Acknowledgments
We thank Mr. Toyokazu Ishikawa of Kanonji Institute, the
Research Foundation for Microbial Diseases of Osaka University
(BIKEN) (Kanonji, Kagawa, Japan) for providingWN-VAX.We
also thank Dr. Soichi Nukuzuma, Kobe Institute of Health (Kobe,
Hyogo, Japan) for supplying a standard density of in vitro-
synthesizedWNvirus NY99RNA. This workwas supported by a
grant for Research on Emerging and Re-emerging Infectious
Diseases from the Ministry of Health, Labour and Welfare of
Japan (H17-Shinko-Ippan-018).
References
Aberle, J.H., Aberle, S.W., Kofler, R.M., Mandl, C.W., 2005. Humoral and
cellular immune response to RNA immunization with flavivirus replicons
derived from tick—borne encephalitis virus. J. Virol. 79, 15107–15113.
Beasley, D.W., Barrett, A.D., 2002. Identification of neutralizing epitopes within
structural domain III of the West Nile virus envelope protein. J. Virol. 76,
13097–13100.
Brinton, M.A., Arnheiter, H., Haller, O., 1982. Interferon independence of ge-
netically controlled resistance to flaviviruses. Infect. Immun. 36, 284–288.
Bunning, M.L., Bowen, R.A., Cropp, C.B., Sullivan, K.G., Davis, B.S., Komar,
N., Godsey, M.S., Baker, D., Hettler, D.L., Holmes, D.A., Biggerstaff, B.J.,
69C.-K. Lim et al. / Virology 374 (2008) 60–70Mitchell, C.J., 2002. Experimental infection of horses with West Nile virus.
Emerg. Infect. Dis. 8, 380–386.
Campbell, G.L., Marfin, A.A., Lanciotti, R.S., Gubler, D.J., 2002. West Nile
virus. Lancet Infect. Dis. 2, 519–529.
Center for Disease Control and Prevention (CDC), 2006a. Assessing capacity for
surveillance, prevention, and control of West Nile virus infection—United
States, 1999 and 2004. MMWR Morb. Mortal. Wkly. Rep. 55, 150–153.
Center for Disease Control and Prevention (CDC), 2006b. West Nile virus
activity—United States, January 1–November 7, 2006. MMWR Morb.
Mortal. Wkly. Rep. 55, 1204–1205.
Chambers, T.J., Hahn, C.S., Galler, R., Rice, C.M., 1990. Flavivirus genome
organization, expression, and replication. Annu. Rev. Microbiol. 44, 649–688.
Chang, G.J., Davis, B.S., Stringfield, C., Lutz, C., 2007. Prospective im-
munization of the endangered California condors (Gymnogyps california-
nus) protects this species from lethal West Nile virus infection. Vaccine 25,
2325–2330.
Davidson, A.H., Traub-Dargatz, J.L., Rodeheaver, R.M., Ostlund, E.N., Pedersen,
D.D., Moorhead, R.G., Stricklin, J.B., Dewell, R.D., Roach, S.D., Long, R.E.,
Albers, S.J., Callan, R.J., Salman,M.D., 2005. Immunologic responses toWest
Nile virus in vaccinated and clinically affected horses. J. Am. Vet.Med. Assoc.
226, 240–245.
Elizondo-Quiroga, D., Davis, C.T., Fernandez-Salas, I., Escobar-Lopez, R.,
Velasco Olmos, D., Soto Gastalum, L.C., Aviles Acosta, M., Elizondo-
Quiroga, A., Gonzalez-Rojas, J.I., Contreras Cordero, J.F., Guzman, H.,
Travassos da Rosa, A., Blitvich, B.J., Barrett, A.D., Beaty, B.J., Tesh, R.B.,
2005. West Nile Virus isolation in human and mosquitoes, Mexico. Emerg.
Infect. Dis. 11, 1449–1452.
Garcia-Tapia, D., Hassett, D.E., Mitchell Jr., W.J., Johnson, G.C., Kleiboeker,
S.B., 2007. West Nile virus encephalitis: sequential histopathological and
immunological events in a murine model of infection. J. Neurovirol. 13,
130–138.
Giladi, M., Metzkor-Cotter, E., Martin, D.A., Siegman-Igra, Y., Korczyn, A.D.,
Rosso, R., Berger, S.A., Campbell, G.L., Lanciotti, R.S., 2001. West Nile
encephalitis in Israel, 1999: the New York connection. Emerg. Infect. Dis. 7,
659–661.
Hamano, M., Lim, C.K., Takagi, H., Sawabe, K., Kuwayama, M., Kishi, N.,
Kurane, I., Takasaki, T., 2007. Detection of antibodies to Japanese ence-
phalitis virus in the wild boars in Hiroshima prefecture, Japan. Epidemiol.
Infect. 1–4.
Hammon, W.M., Sather, G.E., 1956. Immunity of hamsters to West Nile and
Murray Valley viruses following immunization with St. Louis and Japanese
B. Proc. Soc. Exp. Biol. Med. 91, 521–524.
Hayes, E.B., Komar, N., Nasci, R.S., Montgomery, S.P., O'Leary, D.R.,
Campbell, G.L., 2005. Epidemiology and transmission dynamics of West
Nile virus disease. Emerg. Infect. Dis. 11, 1167–1173.
Hoke, C.H., Nisalak, A., Sangawhipa, N., Jatanasen, S., Laorakapongse, T.,
Innis, B.L., Kotchasenee, S., Gingrich, J.B., Latendresse, J., Fukai, K., et al.,
1988. Protection against Japanese encephalitis by inactivated vaccines.
N. Engl. J. Med. 319, 608–614.
Ishikawa, T., 2005. Development of new Japanese encephalitis vaccine. Nippon
Rinsho 63, 2133–2137 (In Japanese).
Ishikawa, T., 2007. West Nile vaccine. World Focus 97, 1–2 (In Japanese).
Kanesa-Thasan, N., Putnak, J.R., Mangiafico, J.A., Saluzzo, J.E., Ludwig, G.V.,
2002. Short report: absence of protective neutralizing antibodies to West
Nile virus in subjects following vaccination with Japanese encephalitis or
dengue vaccines. Am. J. Trop. Med. Hyg. 66, 115–116.
Kayser, M., Klein, H., Paasch, I., Pilaski, J., Blenk, H., Heeg, K., 1985. Human
antibody response to immunization with 17D yellow fever and inactivated
TBE vaccine. J. Med. Virol. 17, 35–45.
Konishi, E., Ajiro, N., Nukuzuma, C., Mason, P.W., Kurane, I., 2003.
Comparison of protective efficacies of plasmid DNAs encoding Japanese
encephalitis virus proteins that induce neutralizing antibody or cytotoxic T
lymphocytes in mice. Vaccine 21, 3675–3683.
Kuno, G., Chang, G.J., Tsuchiya, K.R., Karabatsos, N., Cropp, C.B., 1998.
Phylogeny of the genus Flavivirus. J. Virol. 72, 73–83.
Kurane, I., Takasaki, T., 2000. Immunogenicity and protective efficacy of the
current inactivated Japanese encephalitis vaccine against different Japanese
encephalitis virus strains. Vaccine 18 (Sl–S2), 33–35.Le Guenno, B., Bougermouh, A., Azzam, T., Bouakaz, R., 1996. West Nile: a
deadly virus? Lancet 348, 1315.
Lvov, D.K., Butenko, A.M., Gromashevsky, V.L., Larichev, V.P., Gaidamovich,
S.Y., Vyshemirsky, O.I., Zhukov, A.N., Lazorenko, V.V., Salko, V.N.,
Kovtunov, A.I., Galimzyanov, K.M., Platonov, A.E., Morozova, T.N.,
Khutoretskaya, N.V., Shishkina, E.O., Skvortsova, T.M., 2000. Isolation of
two strains of West Nile virus during an outbreak in southern Russia, 1999.
Emerg. Infect. Dis. 6, 373–376.
Mackenzie, J.S., Gubler, D.J., Petersen, L.R., 2004. Emerging flaviviruses: the
spread and resurgence of Japanese encephalitis, West Nile and dengue
viruses. Nat. Med. 10, S98–S109.
Minke, J.M., Siger, L., Karaca, K., Austgen, L., Gordy, P., Bowen, R., Renshaw,
R.W., Loosmore, S., Audonnet, J.C., Nordgren, B., 2004. Recombinant
canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects
horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. 18,
221–230.
Miura, K., Goto, N., Suzuki, H., Fujisaki, Y., 1988. Strain difference of mouse in
susceptibility to Japanese encephalitis virus infection. Jikken Dobutsu 37,
365–373.
Morales, M.A., Barrandeguy, M., Fabbri, C., Garcia, J.B., Vissani, A., Trono, K.,
Gutierrez, G., Pigretti, S., Menchaca, H., Garrido, N., Taylor, N., Fernandez,
F., Levis, S., Enria, D., 2006. West Nile virus isolation from equines in
Argentina, 2006. Emerg. Infect. Dis. 12, 1559–1561.
Mukhopadhyay, S., Kuhn, R.J., Rossmann, M.G., 2005. A structural perspective
of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13–22.
Murgue, B., Murri, S., Triki, H., Deubel, V., Zeller, H.G., 2001. West Nile in the
Mediterranean basin: 1950–2000. Ann. N. Y. Acad. Sci. 951, 117–126.
Nash, D., Mostashari, F., Fine, A., Miller, J., O'Leary, D., Murray, K., Huang,
A., Rosenberg, A., Greenberg, A., Sherman, M., Wong, S., Layton, M., 1999
West Nile Outbreak Response Working Group, 2001. The outbreak of West
Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344,
1807–1814.
Ng, T., Hathaway, D., Jennings, N., Champ, D., Chiang, Y.W., Chu, H.J., 2003.
Equine vaccine for West Nile virus. Dev. Biol. (Basel). 114, 221–227.
Okuno, Y., Fukunaga, T., Tadano, M., Okamoto, Y., Ohnishi, T., Takagi, M.,
1985. Rapid focus reduction neutralization test of Japanese encephalitis
virus in microtiter system. Brief report. Arch. Virol. 86, 129–135.
Okuno, Y., Igarashi, A., Fukai, K., 1978. Neutralization tests for dengue and
Japanese encephalitis viruses by the focus reduction method using
peroxidase–anti-peroxidase staining. Biken J. 21, 137–147.
Oya, A., 1988. Japanese encephalitis vaccine. Acta. Paediatr. Jpn. 30, 175–184.
Pepperell, C., Rau, N., Krajden, S., Kern, R., Humar, A., Mederski, B., Simor,
A., Low, D.E., McGeer, A., Mazzulli, T., Burton, J., Jaigobin, C., Fearon,
M., Artsob, H., Drebot, M.A., Halliday, W., Brunton, J., 2003. West Nile
virus infection in 2002: morbidity and mortality among patients admitted to
hospital in southcentral Ontario. CMAJ 168, 1399–1405.
Perelygin, A.A., Scherbik, S.V., Zhulin, I.B., Stockman, B.M., Li, Y., Brinton,
M.A., 2002. Positional cloning of the murine flavivirus resistance gene.
Proc. Natl. Acad. Sci. U. S. A. 99, 9322–9327.
Petersen, L.R., Marfin, A.A., 2002. West Nile virus: a primer for the clinician.
Ann. Intern. Med. 137, 173–179.
Pugachev, K.V., Guirakhoo, F., Trent, D.W., Monath, T.P., 2003. Traditional and
novel approaches to flavivirus vaccines. Int. J. Parasitol. 33, 567–582.
Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent end
points. Am. J. Hyg. 27, 493–497.
Seino, K.K., Long, M.T., Gibbs, E.P., Bowen, R.A., Beachboard, S.E.,
Humphrey, P.P., Dixon, M.A., Bourgeois, M.A., 2007. Comparative
efficacies of three commercially available vaccines against West Nile virus
(WNV) in a short-duration challenge trial involving an equine WNV
encephalitis model. Clin. Vaccine. Immunol. 14, 1465–1471.
Smithburn, K.C., Hughes, T.P., Burke, A.W., Paul, J.H., 1940. A neurotropic
virus isolated from the blood of a native of Uganda. Am. J. Trop. Med. 20,
471–492.
Sohn, Y.M., 2000. Japanese encephalitis immunization in South Korea: past,
present, and future. Emerg. Infect. Dis. 6, 17–24.
Solomon, T., Ni, H., Beasley, D.W., Ekkelenkamp, M., Cardosa, M.J., Barrett,
A.D., 2003. Origin and evolution of Japanese encephalitis virus in southeast
Asia. J. Virol. 77, 3091–3098.
70 C.-K. Lim et al. / Virology 374 (2008) 60–70Srivastava, A.K., Putnak, J.R., Lee, S.H., Hong, S.P., Moon, S.B., Barvir, D.A.,
Zhao, B., Olson, R.A., Kim, S.O., Yoo, W.D., Towle, A.C., Vaughn, D.W.,
Innis, B.L., Eckels, K.H., 2001. A purified inactivated Japanese encephalitis
virus vaccine made in Vero cells. Vaccine 19, 4557–4565.
Takasaki, T., Yabe, S., Nerome, R., Ito, M., Yamada, K., Kurane, I., 2003. Partial
protective effect of inactivated Japanese encephalitis vaccine on lethal West
Nile virus infection in mice. Vaccine 21, 4514–4518.
Tesh, R.B., Arroyo, J., Travassos da Rosa, A.P., Guzman, H., Xiao, S.Y.,
Monath, T.P., 2002a. Efficacy of killed virus vaccine, live attenuated
chimeric virus vaccine, and passive immunization for prevention of West
Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8, 1392–1397.
Tesh, R.B., Travassos da Rosa, A.P., Guzman, H., Araujo, T.P., Xiao, S.Y.,
2002b. Immunization with heterologous flaviviruses protective against fatal
West Nile encephalitis. Emerg. Infect. Dis. 8, 245–251.
Tiroumourougane, S.V., Raghava, P., Srinivasan, S., 2002. Japanese viral
encephalitis. Postgrad. Med. J. 78, 205–215.
Tsai, T.F., 2000. New initiatives for the control of Japanese encephalitis by
vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15
October 1998. Vaccine 18 (Suppl 2), 1–25.Tsai, T.F., Popovici, F., Cernescu, C., Campbell, G.L., Nedelcu, N.I., 1998. West
Nile encephalitis epidemic in southeastern Romania. Lancet 352, 767–771.
Turell, M.J., Bunning, M., Ludwig, G.V., Ortman, B., Chang, J., Speaker, T.,
Spielman, A., McLean, R., Komar, N., Gates, R., McNamara, T., Creekmore,
T., Farley, L., Mitchell, C.J., 2003. DNAvaccine forWest Nile virus infection
in fish crows (Corvus ossifragus). Emerg. Infect. Dis. 9, 1077–1081.
Yamada, K., Takasaki, T., Nawa, M., Yabe, S., Kurane, I., 2003. Antibody
responses determined for Japanese dengue fever patients by neutralization
and hemagglutination inhibition assays demonstrate cross-reactivity
between dengue and Japanese encephalitis viruses. Clin. Diagn. Lab.
Immunol. 10, 725–728.
Yamshchikov, G., Borisevich, V., Kwok, C.W., Nistler, R., Kohlmeier, J.,
Seregin, A., Chaporgina, E., Benedict, S., Yamshchikov, V., 2005. The
suitability of yellow fever and Japanese encephalitis vaccines for immu-
nization against West Nile virus. Vaccine 23, 4785–4792.
Yang, J.S., Kim, J.J., Hwang, D., Choo, A.Y., Dang, K., Maguire, H.,
Kudchodkar, S., Ramanathan, M.P., Weiner, D.B., 2001. Induction of potent
Th1-type immune responses from a novel DNA vaccine for West Nile virus
New York isolate (WNV-NY1999). J. Infect. Dis. 184, 809–816.
